Cannabinoid Receptors As Novel Targets for the Treatment of Melanoma.
From: Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040 Madrid, Spain.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- Publish Date: Dec 2006
- ISSN: 1530-6860
- Volume: 20
- Issue: 14
- Pages: 2633-5
- Medium: Internet
- Language: English
- Citation (JAMA): Blázquez Cristina, Carracedo Arkaitz, Barrado Lucía, et al. Cannabinoid Receptors As Novel Targets for the Treatment of Melanoma.. FASEB J. Dec 2006;20:2633-5
Abstract
Melanoma causes the greatest number of skin cancer-related deaths worldwide. Despite intensive research, prevention and early detection are the only effective measures against melanoma, so new therapeutic strategies are necessary for the management of this devastating disease. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis and metastasis, and increased apoptosis, of melanomas in mice. Cannabinoid antimelanoma activity was independent of the immune status of the animal, could be achieved without overt psychoactive effects and was selective for melanoma cells vs. normal melanocytes. Cannabinoid antiproliferative action on melanoma cells was due, at least in part, to cell cycle arrest at the G1-S transition via inhibition of the prosurvival protein Akt and hypophosphorylation of the pRb retinoblastoma protein tumor suppressor. These findings may contribute to the design of new chemotherapeutic strategies for the management of melanoma.
Mesh Headings (Keywords): Animals, Antineoplastic Agents, Cannabinoids, Cell Cycle, Cell Line, Tumor, Gene Expression Regulation, Humans, Melanocytes, Melanoma, Mice, Neovascularization, Pathologic, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2
Check for Full Text / PubMed Unique Identifier (PMID): 17065222
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.